{"id":"W4415756350","doi":"10.1016/j.jhepr.2025.101658","title":"Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib – A phase II trial (PEMRAD)","year":2025,"lang":"en","type":"article","venue":"JHEP Reports","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"Merck Canada; Princess Margaret Cancer Foundation; Merck","keywords":"Pembrolizumab; Sorafenib; Hepatocellular carcinoma; Clinical trial; Radiation therapy; Hepatocellular cancer; Stereotactic radiotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004048458,0.0004107551,0.0009310654,0.0004759051,0.0001885205,0.00005528486,0.00007770176,0.0002162449,0.000137218],"category_scores_gemma":[0.0001514889,0.0003721406,0.000245403,0.000486744,0.00009285437,0.0001862856,0.0000737255,0.0003021824,0.000002946086],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002657859,"about_ca_system_score_gemma":0.0004468221,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000289283,"about_ca_topic_score_gemma":0.00002044128,"domain_scores_codex":[0.9973601,0.0001330417,0.0009326033,0.0007736024,0.0003293579,0.0004712801],"domain_scores_gemma":[0.9985037,0.00009515497,0.000282952,0.0007542229,0.0001231462,0.000240789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04429711,0.002920217,0.913114,0.0001990567,0.0002709948,0.01704086,0.0004467866,1.680726e-7,0.01346267,0.0001109845,0.0002029744,0.007934147],"study_design_scores_gemma":[0.6898968,0.03198191,0.2057775,0.0007713765,0.001669567,0.003677093,0.0002847329,0.01202353,0.02932882,0.0008922654,0.02214371,0.001552716],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892504,0.003972805,0.00002846038,0.001291316,0.0005506858,0.003316717,0.000007033247,0.0001154471,0.001467134],"genre_scores_gemma":[0.9964522,0.0001199789,0.0002636099,0.0003726383,0.0001114276,0.0003421047,0.0001516963,0.00005106439,0.002135315],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7073365,"threshold_uncertainty_score":0.999873,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02267633328266469,"score_gpt":0.2841846377125806,"score_spread":0.2615083044299159,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}